Elranatamab
Pfizer
['multiplemyeloma', 'pfizer']
the study design for the phase 1b/2 magnetismm-4 study evaluating bcma-cd3 bispecific antibody (bsab)-based regimens for patients with #multiplemyeloma is being presented at #ash22 4567 
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ